|
Medarex Incorporated - Company Profile Snapshot
| Company Profile: |
Medarex Incorporated |
| Ticker: |
MEDX |
| Exchanges: |
NAS |
| 2008 Sales: |
52,292,000 |
| Major Industry: |
Drugs, Cosmetics & Health Care |
| Sub Industry: |
Ethical Drug Manufacturers |
| Country: |
UNITED STATES |
| Employees: |
488 |
Business Description
Medarex Incorporated. The Group's principal activities are to discover and develop human antibody-based therapeutic products. The Group uses its proprietary technology platform, the UltiMAb Human Antibody Development System to rapidly create and develop therapeutic products for the treatment of cancer, inflammation, auto-immune disease and other life-threatening and debilitating diseases. The Group's therapeutic product candidates are currently under development and include MDX-33, MDX-010, HuMax(TM)-CD4, HuMax-IL15, Centocor/J&J Antibody and MDX-070. As of 01-Feb-2008, the Group had licensing and collaborative partnerships with more than 35 pharmaceutical and biotechnology companies either to jointly develop and commercialize products or use the Group's proprietary technology in the development of new therapeutic products.
|
Not the Report you are looking for?
Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
